pharma · Multiple Myeloma · Relapsed/Refractory Multiple Myeloma
Janssen-Cilag International N.V
Janssen-Cilag International N.V.
Janssen-Cilag Farmaceutica Ltda is a pharma organization headquartered in São Paulo, EU. Primary therapeutic focus areas include Multiple Myeloma, Relapsed/Refractory Multiple Myeloma, Inflammatory Conditions, Moderately
Company details
- Status
- Public
- HQ
- São Paulo, EU
- Employees
- 13
- Programs
- 161
- Drugs
- 159
- Patents
- 0
CNTO1959ISD3001
Phase 3 · small molecule · Juvenile psoriatic arthritis (jPsA), Moderately to severely active ulcerative colitis (UC), Moderately to severely active Crohn's disease (CD)
CNTO1959ISD3001 for Juvenile psoriatic arthritis (jPsA), Moderately to severely active ulcerative colitis (UC), Moderately to severely active Crohn's disease (CD) is a Phase 3 program (small_molecule) at Janssen-Cilag International N.V. with 1 ClinicalTrials.gov record(s).
Internal code CNTO1959ISD3001
Full intelligence profile for this program is being prepared.
At a glance
- Sponsor
- Janssen-Cilag International N.V.
- Phase
- Phase 3
- Modality
- small_molecule
- Indication
- Juvenile psoriatic arthritis (jPsA), Moderately to severely active ulcerative colitis (UC), Moderately to severely active Crohn's disease (CD)
- Status
- active
- Trials
- 1